NervGen Pharma Corp.
NGENF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.67 | 2.53 | -0.19 | 0.97 |
| FCF Yield | -7.98% | -7.88% | -20.99% | -7.86% |
| EV / EBITDA | -7.80 | -7.55 | -2.76 | -6.96 |
| Quality | ||||
| ROIC | -929.53% | 981.10% | -166.06% | -76.50% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.70 | 0.50 | 0.86 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -47.25% | 35.77% | -114.15% | -31.76% |
| Safety | ||||
| Net Debt / EBITDA | 0.69 | 0.65 | 0.98 | 1.33 |
| Interest Coverage | 0.00 | 0.00 | -44.35 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,385.46 | -6,347.61 | -3,018.80 |